Life Extension Update
JAMA meta-analysis confirms link between premature mortality and obesity
Tuesday, January 8, 2013. The January 2, 2013 issue of the Journal of the American Medical Association (JAMA) reported the outcome of a meta-analysis conducted by researchers at the National Center for Health Statistics, Centers for Disease Control and Prevention in Hyattsville, Maryland, which reaffirmed the link between being obese and having a greater risk of dying from all causes over follow-up.
Katherine M. Flegal, PhD and her associates reviewed 97 studies that included a total of over 2.88 million individuals, among whom there were 270,000 deaths. Subjects were considered normal weight if their body mass index (BMI) was between 18.5 and less than 25, and those with a BMI between 25 and less than 30 were classified as overweight. (Body mass index is calculated by dividing weight in kilograms by height in meters squared.) Among those considered obese, a BMI ranging from 30 to less than 35 was classified as grade 1, a BMI of 35 to less than 40 was categorized as grade 2 and grade 4 was applied to subjects with a BMI of 40 or higher.
Obese men and women had a 5 percent higher risk of dying over follow up in comparison with those whose BMI was normal. Interestingly, when obesity was examined according to grade, having grade 2 and 3 obesity was associated with a 29 percent higher risk of dying, but being classified as grade 1 was associated with a 5 percent lower risk. Being overweight but not obese was similarly associated with a lower risk of mortality over follow-up. "Possible explanations have included earlier presentation of heavier patients, greater likelihood of receiving optimal medical treatment, cardioprotective metabolic effects of increased body fat, and benefits of higher metabolic reserves," the authors suggest.
"Our study also has limitations," they note. "It addresses only all-cause mortality and not morbidity or cause-specific mortality. It addresses only findings related to BMI and not to other aspects of body composition such as visceral fat or fat distribution."
In an accompanying editorial, Steven B. Heymsfield, MD, and William T. Cefalu, MD observe that "The presence of a wasting disease, heart disease, diabetes, renal dialysis, or older age are all associated with an inverse relationship between BMI and mortality rate, an observation termed the obesity paradox or reverse epidemiology. The optimal BMI linked with lowest mortality in patients with chronic disease may be within the overweight and obesity range. Even in the absence of chronic disease, small excess amounts of adipose tissue may provide needed energy reserves during acute catabolic illnesses, have beneficial mechanical effects with some types of traumatic injuries, and convey other salutary effects that need to be investigated."
Despite the possibility of a protective effect for excess weight in some cases, Drs Heymsfield and Cefalu remark that in addition to BMI, traditional risk factors such as blood pressure, lipid levels, fasting glucose and waist circumference, as well as more newly recognized markers including those that assess inflammation could improve the identification of those at risk of early mortality.
UC-II® is a registered trademark of InterHealth Nutraceuticals, Inc. U.S. Patent Nos. 5,645,851, 5,637,321, 5,529,786, 5,750,144, 7,083,820, 7,846,487, EP1435906 B1 and worldwide patents pending.
This supplement should be taken in conjunction with a healthy diet and regular exercise program. Individual results are not guaranteed and results may vary.
The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.
If you are not 100% satisfied with any purchase made directly from Life Extension®, just return your purchase within 12 months of original purchase date and we will either replace the product for you, credit your original payment method or credit your Life Extension account for the full amount of the original purchase price (less shipping and handling).
These statements have not been evaluated by the Food and Drug Administration.
These products are not intended to diagnose, treat, cure, or prevent any disease.